Optikira is Drug Discovery in United States that focus on various neurodegenerative diseases business. Founded in 2014. They cover business area such as developer, novel therapeutic, cell death, UPR, its activity, cell degeneration, idiopathic pulmonary fibrosis, nonalcoholic steatohepatitis, cancer, diabetes, various neurodegenerative disease, medical practitioner, Retinitis pigmentosa, amyotrophic lateral sclerosis.
2014
( 10 years old in 2024 )
Various Neurodegenerative Diseases
-
20600 Chagrin Boulevard
Suite 210
Cleveland, OH 44122
United States
Private
developernovel therapeuticcell deathUPRits activitycell degenerationidiopathic pulmonary fibrosisnonalcoholic steatohepatitiscancerdiabetesvarious neurodegenerative diseasemedical practitionerRetinitis pigmentosaamyotrophic lateral sclerosis
* We use standard office opening hours in near Optikira's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
Optikira is Drug Discovery business from United States that founded in 2014 (10 years old in 2024), Optikira business is focusing on Various Neurodegenerative Diseases.
Optikira headquarter office and corporate office address is located in 20600 Chagrin Boulevard Suite 210 Cleveland, OH 44122 United States.
Optikira was founded in United States.
In 2024, Optikira is currently focus on various neurodegenerative diseases sector.
Above is snippet of Google Trends for "various neurodegenerative diseases" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with Optikira, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
